Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Zivo Bioscience, Inc.ZIVO · Entity 9611 | Chief Financial Officer | June 05, 2024 | June 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Zivo Bioscience, Inc.
Report date June 05, 2024 · Filed June 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Nonstatutory Stock Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $67.20 · Expires 2030-12-31 | Direct | 0 |
Reported balance
After 2024-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-05 · Disposition to issuer · Disposed 27,083 · Balance 0 F1: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 80 reverse stock split of the Issuer's stock in May 2021 and a 1 for 6 reverse stock split of the Issuer's stock in October 2023, as applicable. F3: The Issuer canceled options for an aggregate 85,416 shares of the Issuer's common stock granted to the Reporting Person on 1/1/2021, 10/21/2021, and 8/29/2022. In exchange for the canceled options, the Reporting Person received a replacement option, for 444,498 shares, having an exercise price of $7.96. F2: The canceled option was fully vested. |
| Nonstatutory Stock Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $33.00 · Expires 2031-10-20 | Direct | 0 |
Reported balance
After 2024-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-05 · Disposition to issuer · Disposed 48,000 · Balance 0 F1: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 80 reverse stock split of the Issuer's stock in May 2021 and a 1 for 6 reverse stock split of the Issuer's stock in October 2023, as applicable. F3: The Issuer canceled options for an aggregate 85,416 shares of the Issuer's common stock granted to the Reporting Person on 1/1/2021, 10/21/2021, and 8/29/2022. In exchange for the canceled options, the Reporting Person received a replacement option, for 444,498 shares, having an exercise price of $7.96. F4: The canceled option was issued pursuant to the 2021 Equity Incentive Plan on 10/21/2021 and vested as follows: 25% upon acceptance of the grant, and 25% on each of the next three calendar anniversaries of the grant. |
| Nonstatutory Stock Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $23.64 · Expires 2032-08-28 | Direct | 0 |
Reported balance
After 2024-06-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-05 · Disposition to issuer · Disposed 10,333 · Balance 0 F1: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 80 reverse stock split of the Issuer's stock in May 2021 and a 1 for 6 reverse stock split of the Issuer's stock in October 2023, as applicable. F3: The Issuer canceled options for an aggregate 85,416 shares of the Issuer's common stock granted to the Reporting Person on 1/1/2021, 10/21/2021, and 8/29/2022. In exchange for the canceled options, the Reporting Person received a replacement option, for 444,498 shares, having an exercise price of $7.96. F5: The canceled option was issued pursuant to the 2021 Equity Incentive Plan on 8/29/2022 and vested as follows: 25% upon acceptance of the grant, and 25% on each of the next three calendar anniversaries of the grant. |
| Nonstatutory Stock Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $7.96 · Expires 2034-06-04 | Direct | 444,498 |
Reported balance
After 2024-06-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-06-05 · Grant · Acquired 444,498 · Balance 444,498 F3: The Issuer canceled options for an aggregate 85,416 shares of the Issuer's common stock granted to the Reporting Person on 1/1/2021, 10/21/2021, and 8/29/2022. In exchange for the canceled options, the Reporting Person received a replacement option, for 444,498 shares, having an exercise price of $7.96. F6: The option was issued pursuant to the 2021 Equity Incentive Plan and vests as follows: 328,065 immediately upon grant acceptance, 13,551 on July 1, 2024, 13,442 on August 28, 2024, 62,447 on October 21, 2024, 13,551 on January 1, 2025, and 13,442 on August 28, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 80 reverse stock split of the Issuer's stock in May 2021 and a 1 for 6 reverse stock split of the Issuer's stock in October 2023, as applicable.
F2: The canceled option was fully vested.
F3: The Issuer canceled options for an aggregate 85,416 shares of the Issuer's common stock granted to the Reporting Person on 1/1/2021, 10/21/2021, and 8/29/2022. In exchange for the canceled options, the Reporting Person received a replacement option, for 444,498 shares, having an exercise price of $7.96.
F4: The canceled option was issued pursuant to the 2021 Equity Incentive Plan on 10/21/2021 and vested as follows: 25% upon acceptance of the grant, and 25% on each of the next three calendar anniversaries of the grant.
F5: The canceled option was issued pursuant to the 2021 Equity Incentive Plan on 8/29/2022 and vested as follows: 25% upon acceptance of the grant, and 25% on each of the next three calendar anniversaries of the grant.
F6: The option was issued pursuant to the 2021 Equity Incentive Plan and vests as follows: 328,065 immediately upon grant acceptance, 13,551 on July 1, 2024, 13,442 on August 28, 2024, 62,447 on October 21, 2024, 13,551 on January 1, 2025, and 13,442 on August 28, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2024 Filed Jun 6, 2024 22:26 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantNonstatutory Stock Option to Purchase Common Stock · Derivative | 444,498 | Not disclosed Strike: $7.96 | Not disclosed |
DisclosureSEC source: 0001654954-24-007461 · section16.xml · derivative · entry 4 Marchiando Keith · CIK 0001291432 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 444,498 Underlying: Common Stock · 444,498 shares Expires 2034-06-04 F3 · price: The Issuer canceled options for an aggregate 85,416 shares of the Issuer's common stock granted to the Reporting Person on 1/1/2021, 10/21/2021, and 8/29/2022. In exchange for the canceled options, the Reporting Person received a replacement option, for 444,498 shares, having an exercise price of $7.96. F6 · derivative.exercise_date: The option was issued pursuant to the 2021 Equity Incentive Plan and vests as follows: 328,065 immediately upon grant acceptance, 13,551 on July 1, 2024, 13,442 on August 28, 2024, 62,447 on October 21, 2024, 13,551 on January 1, 2025, and 13,442 on August 28, 2025. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:26 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Disposition to issuerNonstatutory Stock Option to Purchase Common Stock · Derivative | 10,333 | Not disclosed Strike: $23.64 | Not disclosed |
DisclosureSEC source: 0001654954-24-007461 · section16.xml · derivative · entry 3 Marchiando Keith · CIK 0001291432 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,333 shares Expires 2032-08-28 F1 · derivative.exercise_price: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 80 reverse stock split of the Issuer's stock in May 2021 and a 1 for 6 reverse stock split of the Issuer's stock in October 2023, as applicable. F1 · shares: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 80 reverse stock split of the Issuer's stock in May 2021 and a 1 for 6 reverse stock split of the Issuer's stock in October 2023, as applicable. F3 · price: The Issuer canceled options for an aggregate 85,416 shares of the Issuer's common stock granted to the Reporting Person on 1/1/2021, 10/21/2021, and 8/29/2022. In exchange for the canceled options, the Reporting Person received a replacement option, for 444,498 shares, having an exercise price of $7.96. F5 · derivative.exercise_date: The canceled option was issued pursuant to the 2021 Equity Incentive Plan on 8/29/2022 and vested as follows: 25% upon acceptance of the grant, and 25% on each of the next three calendar anniversaries of the grant. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:26 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Disposition to issuerNonstatutory Stock Option to Purchase Common Stock · Derivative | 48,000 | Not disclosed Strike: $33.00 | Not disclosed |
DisclosureSEC source: 0001654954-24-007461 · section16.xml · derivative · entry 2 Marchiando Keith · CIK 0001291432 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,000 shares Expires 2031-10-20 F1 · derivative.exercise_price: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 80 reverse stock split of the Issuer's stock in May 2021 and a 1 for 6 reverse stock split of the Issuer's stock in October 2023, as applicable. F1 · shares: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 80 reverse stock split of the Issuer's stock in May 2021 and a 1 for 6 reverse stock split of the Issuer's stock in October 2023, as applicable. F3 · price: The Issuer canceled options for an aggregate 85,416 shares of the Issuer's common stock granted to the Reporting Person on 1/1/2021, 10/21/2021, and 8/29/2022. In exchange for the canceled options, the Reporting Person received a replacement option, for 444,498 shares, having an exercise price of $7.96. F4 · derivative.exercise_date: The canceled option was issued pursuant to the 2021 Equity Incentive Plan on 10/21/2021 and vested as follows: 25% upon acceptance of the grant, and 25% on each of the next three calendar anniversaries of the grant. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 22:26 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | Disposition to issuerNonstatutory Stock Option to Purchase Common Stock · Derivative | 27,083 | Not disclosed Strike: $67.20 | Not disclosed |
DisclosureSEC source: 0001654954-24-007461 · section16.xml · derivative · entry 1 Marchiando Keith · CIK 0001291432 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,083 shares Expires 2030-12-31 F1 · derivative.exercise_price: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 80 reverse stock split of the Issuer's stock in May 2021 and a 1 for 6 reverse stock split of the Issuer's stock in October 2023, as applicable. F1 · shares: The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 80 reverse stock split of the Issuer's stock in May 2021 and a 1 for 6 reverse stock split of the Issuer's stock in October 2023, as applicable. F3 · price: The Issuer canceled options for an aggregate 85,416 shares of the Issuer's common stock granted to the Reporting Person on 1/1/2021, 10/21/2021, and 8/29/2022. In exchange for the canceled options, the Reporting Person received a replacement option, for 444,498 shares, having an exercise price of $7.96. F2 · derivative.exercise_date: The canceled option was fully vested. Read SEC document |
| August 29, 2022 Filed Aug 31, 2022 20:12 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantNonstatutory Stock Option to Purchase Common Stock · Derivative | 62,000 | $0.00 Strike: $3.94 | $0.00 |
DisclosureSEC source: 0001654954-22-012022 · section16.xml · derivative · entry 1 Marchiando Keith · CIK 0001291432 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2022-08-28 F1 · derivative.exercise_date: The option was issued pursuant to the 2021 Equity Incentive Plan and vests as follows: 25% upon acceptance of the grant, and 25% on each of the next three calendar anniversaries of the grant. Read SEC document |
| October 21, 2021 Filed Oct 25, 2021 23:06 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantNonstatutory Stock Option to Purchase Common Stock · Derivative | 288,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001654954-21-011336 · section16.xml · derivative · entry 1 Marchiando Keith · CIK 0001291432 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,000 Underlying: Common Stock · 288,000 shares Expires 2031-10-20 F1 · derivative.exercise_date: The option was issued pursuant to the 2021 Equity Incentive Plan and vests as follows: 25% upon acceptance of the grant, and 25% on each of the next three calendar anniversaries of the grant. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 21:51 UTC | Zivo Bioscience, Inc. ZIVO · Entity 9611 | GrantOption to Purchase Common Stock · Derivative | 13,000,000 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001078782-21-000005 · primary_doc.xml · derivative · entry 1 Marchiando Keith · CIK 0001291432 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000,000 Underlying: Common Stock · 13,000,000 shares Expires 2030-12-31 F1 · derivative.exercise_date: 3,000,000 vested immediately, and 1,250,000 shares will vest on each six month anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.